$SGYP GI Drug Developer with Phase 2b/3 Results Expected in Early January
publication date: Nov 19, 2012
Written by Mike Havrilla--Synergy Pharma (SGYP) is focused on the development of new treatments for gastrointestinal (GI) disorders, including lead product candidate Plecanatide...
Sorry this page is available to subscribers only. If you're not a subscriber why not join today?
If you are already a subscriber, please login.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site including:
- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily
- Members Only Live Interactive Webinars
- Live Chat Room
- Video Lessons / Trade Reviews
- Chart / Technical Analysis
- Run-Up Valuation Studies
- Weekly Watchlist Newsletter
- Email / SMS (Text Message) Alerts of critical news
- Access to view Mark Messier and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Historical FDA Tracker
- Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates
- Direct Email Communication
- Affiliate Program
If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.
